m6A修饰在卵巢癌中的研究进展  

Role of m6A modification in ovarian cancer:A review of literature

作　　者：彭佳欣 张自辉 洪莉[1] PENG Jiaxin;ZHANG Zihui;HONG Li(Department of Obstetrics and Gynecology,Renmin Hospital,Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院妇产科,武汉430060

出　　处：《实用医学杂志》2023年第12期1577-1583,共7页The Journal of Practical Medicine

基　　金：国家重点研发计划项目子课题(编号:2018YFC2002204);湖北省第二届医学领军人才工程第二层次基金(编号:[2019]47)。

摘　　要：卵巢癌是常见的妇科恶性肿瘤,多数患者就诊时已属晚期,加之复发和化疗耐药,卵巢癌患者病死率高,预后差。m6A(N6⁃甲基腺苷)修饰是一种常见的表观遗传学修饰,可动态且可逆地调控RNA代谢的整个过程。近年来有多项研究表明,m6A修饰在卵巢癌患者中表达异常,在肿瘤发生、转移和化疗耐药过程中发挥重要作用,有希望成为卵巢癌的早期诊断或评估预后的潜在肿瘤标志物,m6A的研究也为卵巢癌治疗提供了新的思路。Ovarian cancer is a common gynecological malignancy.Most patients with the cancer are already at an advanced stage when visiting for medical consultations and are prone to recurrence and chemoresistance,so ovarian cancer patients have a high mortality rate and poor prognosis.N6 methyladenosine is a common epigenetic modification that dynamically and reversibly regulates the entire process of RNA metabolism.Recent studies have shown that m6A modification is aberrantly expressed in ovarian cancer patients,which is closely related to tumori⁃genesis,metastasis and chemoresistance.Therefore,m6A can be used as a potential tumor marker for the early diagnosis or assessment of prognosis of ovarian cancer.The recent research of m6A also provides new ideas for the treatment of ovarian cancer.In this paper,we reviewed the role of m6A modification in ovarian cancer.

关 键 词：卵巢癌 m6A 治疗靶点 

分 类 号：R737.31[医药卫生—肿瘤]